ENTX Entera Bio Ltd. stock chart & analysis
Conviction 19HealthcareScan · Wed, Nov 4, 2026Entera Bio Ltd. (ENTX) closed at $3.13 (+2.62%) on Nov 4, 2026. Price is above its 50-day and above its 200-day moving average. RSI(14) 59, RS Rating 96, -25.5% from its 52-week high, +61.3% year to date. Sector: Healthcare · Biological Products, (No Diagnostic Substances).
Why ENTX moved
From the StockSetups movers recaps that covered ENTX, newest first. A recap states what was known that day.
- Close+90.7%
Entera Bio announced the pricing of an oversubscribed $275 million private placement (per Yahoo Finance).
Top Stock Movers Today — July 27, 2026: Why ENTX, FBRX, NIPG & QBTS Surged →
Financials as of Tue, Jun 30, 2026 · quarterly.
ENTX technical analysis
Trend
ENTX is in an uptrend: price is above the 50-day, which is above the 200-day moving average. It closed 8.7% above the 50-day ($2.88) and 62.2% above the 200-day ($1.93). ADX(14) at 26 points to a strong, established trend. It meets 8 of 8 trend-template criteria.
Momentum
RSI(14) is 59, in the bullish half of its range. The MACD histogram is positive. A bearish MACD divergence is in place. Its RS Rating of 96 puts its weighted 12-month performance ahead of about 96% of the US market.
Volume and volatility
Volume on the latest session ran 0.3× its 20-day average. It trades about $1.5M a day on average. ATR(14) is $0.2095, 6.7% of price — its typical daily range. On-balance volume is trending up. Chaikin Money Flow (0.21) shows accumulation.
Key levels
The chart pattern's support is $2.45 and its resistance $3.28. The 52-week range is $0.9100 to $4.20; price is 25.5% below the high and 244.0% above the low. The VWAP anchored at the 52-week high is $3.40, above price.
Performance
ENTX returned +1.0% (1 week), +23.7% (1 month), +11.0% (3 months), +150.4% (6 months), +10.2% (1 year), +61.3% (year to date).
About Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.
Biological Products, (No Diagnostic Substances) · Listed 2018 · 22 employees
Insider activity
SEC Form 4 transactions in ENTX
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Ellis Sean Director · Ordinary Shares, par value NIS 0.0000769 per share · 2026-08-07 | Grant | 20.03K | — | 2026-08-07 | 2026-08-07 |
Ellis Sean Director · Stock Option (right to buy) · 2026-08-07 | Grant | 40K | — | 2026-08-07 | 2026-08-07 |
Burshtein Gregory Chief of R&D · Stock Option (right to buy) · 2026-08-07 | Grant | 180K | — | 2026-08-07 | 2026-08-07 |
Germano Geno J Director · Ordinary Shares, par value NIS 0.0000769 per share · 2026-08-07 | Grant | 25.01K | — | 2026-08-07 | 2026-08-07 |
Germano Geno J Director · Stock Option (right to buy) · 2026-08-07 | Grant | 50K | — | 2026-08-07 | 2026-08-07 |
Germano Geno J Director · Stock Option (right to buy) · 2026-08-07 | Grant | 43.01K | — | 2026-08-07 | 2026-08-07 |
Toledano Miranda Jayne Chief Executive Officer · Stock Option (right to buy) · 2026-08-07 | Grant | 500K | — | 2026-08-07 | 2026-08-07 |
Toledano Miranda Jayne Chief Executive Officer · Stock Option (right to buy) · 2026-08-07 | Grant | 200K | — | 2026-08-07 | 2026-08-07 |
Galitzer Hillel Chief Operating Officer · Stock Option (right to buy) · 2026-08-07 | Grant | 200K | — | 2026-08-07 | 2026-08-07 |
Yaacov-Garbeli Dana Chief Financial Officer · Stock Option (right to buy) · 2026-08-07 | Grant | 140K | — | 2026-08-07 | 2026-08-07 |
SEC filings
EDGAR filings in ENTX · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.
Start free — 7-day trial, no card →Free daily signals by email. Top 3 setups per lane after every close. No account needed.
Unsubscribe anytime · Privacy
Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.